Lung adenocarcinoma is the major cancer type that benefits from molecular targeted therapies, including tyrosine kinase inhibitors targeting the epidermal growth factor receptor (EGFR) mutations or ALK, EMAP-like 4, and neurotrophic receptor tyrosine kinase fusions [7]. Here, EGFR is linked to lung adenocarcinoma.